03:39 PM EST - Resverlogix Corp. : announced that SUSTAIN, a Phase-2b clinical trial comprised of 176 subjects, is fully enrolled. The Cleveland Clinic leads this trial in which all subjects have established atherosclerotic cardiovascular disease (CVD) and low high-density cholesterol (HDL-C). Resverlogix Corp.
shares T.RVX are trading down $0.01 at $1.11.
